Neumora Therapeutics, Inc. (NMRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has a cash flow conversion efficiency ratio of -0.353x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.63 Million) by net assets ($132.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NMRA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Neumora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neumora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pecca Group Bhd
KLSE:5271
|
0.122x |
|
Taiwan Sanyo Electric Co Ltd
TW:1614
|
0.033x |
|
Imperial Brands PLC
LSE:IMB
|
-0.086x |
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
-0.083x |
|
Ginwa Enterprise Group Inc
SHG:600080
|
0.019x |
|
EnviTec Biogas AG
XETRA:ETG
|
0.086x |
|
Teamlease Services Limited
NSE:TEAMLEASE
|
0.042x |
|
Hanoi Beer Alcohol and Beverage JSC
VN:BHN
|
-0.079x |
Annual Cash Flow Conversion Efficiency for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Neumora Therapeutics, Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see NMRA market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $287.06 Million | $-182.94 Million | -0.637x | -83.08% |
| 2023-12-31 | $469.08 Million | $-163.28 Million | -0.348x | -235.38% |
| 2022-12-31 | $-446.85 Million | $-114.90 Million | 0.257x | +10.88% |
| 2021-12-31 | $-325.22 Million | $-75.42 Million | 0.232x | -18.21% |
| 2020-12-31 | $-94.38 Million | $-26.76 Million | 0.284x | -99.98% |
| 2019-12-31 | $-21.00K | $-26.76 Million | 1274.286x | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more